A recent cohort study involving 200 IBD patients identified visceral adiposity, rather than BMI, as a predictive risk factor for a shorter time to IBD flare, particularly for CD patients (90)
The hope is that a GLP-1 receptor agonist (or any other anti-obesity medication) could replace medications for a variety of weight-related comorbidities, she said
The study shows that in addition to improving glycemic control, GLP-1RAs reduce major adverse renal events in diabetic patients [61]
Someone who loses 20% of their body weight while normalizing blood sugar, reducing blood pressure, and improving cholesterol is in a dramatically different health position than their starting point
Dominguez, often see patients via telehealth
Both are supplied strictly for laboratory research use only